FDA Refuses to Review Moderna’s New Flu Shot

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology for influenza.

The FDA has been going back and forth with Moderna for nearly two years since the company submitted Phase 3 data on the vaccine. That data showed the effectiveness of the mRNA flu vaccine, called mRNA 1010.6, when compared to existing flu shots.

[time-brightcove not-tgx=”true”]...